SciSparc Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Annual Report on Form 20-F for Fiscal Year 2026 | 30 Apr 2027 |
Monitoring Framework
Key Performance Indicators
Annual Revenue Annually856K
Annual Net Loss Annually-12.6M
Cash and Cash Equivalents Annually4.6M
Watch Items
- Nasdaq Continued Listing ComplianceTrigger: Failure to maintain minimum stockholders' equity of $2,500,000 or alternative thresholdsAction: Monitor periodic financial reports to ensure ongoing compliance with Nasdaq Continued Listing Rule 5550(b)(1) following the conditional compliance letter received on May 7, 2026.
- NeuroThera Labs Acquisition of CliniQuantumTrigger: Completion of closing conditions and final TSXV regulatory approvalAction: Track the integration of CliniQuantum's quantum-based clinical trial simulation platform and its impact on SciSparc's drug discovery capabilities.
- Going Concern and Capital RunwayTrigger: Depletion of current cash reserves below operational requirementsAction: Evaluate the necessity of additional equity or debt financing to fund clinical-stage pharmaceutical developments.
Research as of 20 Jun 2026